Targeted Therapies in Development for Melanoma
Georgina Long, BSc, PhD, MBBS, FRACP, medical oncologist, translational researcher, Melanoma Institute Australia, The University of Sydney, highlights targeted therapies in development for melanoma.
Clinical Pearls
Georgina Long, BSc, PhD, MBBS, FRACP, medical oncologist, translational researcher, Melanoma Institute Australia, The University of Sydney, highlights targeted therapies in development for melanoma.
- Trials are planned looking at several targeted therapies and combinations of therapies, including CDK 4/6 inhibitors, BRAF or MEK inhibitors combined with MDM2 inhibitors, and BRAF plus MEK inhibitors combined with PD-1 antibodies
- Inhibition at the top of a pathway may not be the most efficacious strategy, as in the case of receptor tyrosine kinase inhibitors
- Long favors approaching treatment with the immune system or with inhibitors of AKT/PI3K, CDK 4/6, or HDAC
Advancing Neoadjuvant Therapy for HER2+ Breast Cancer Through ctDNA Monitoring
December 19th 2024In an interview with Targeted Oncology, Adrienne Waks, MD, provided insights into the significance of the findings from the DAPHNe trial and their clinical implications for patients with HER2-positive breast cancer.
Read More
AI-Driven Deep Learning Model Shows Promise in Standardizing MDS Diagnosis
December 10th 2024In an interview, Palak Dave discussed how artificial intelligence, using deep learning to analyze bone marrow aspirate smear images, could standardize and accelerate the diagnosis of MDS vs pre-MDS conditions.
Read More
Systemic Therapy Choice Linked to Radiosurgery Outcomes in Brain Mets
December 6th 2024In an interview with Targeted OncologyT, Rupesh Kotecha, MD, discussed a study focused on how systemic therapy selection impacts outcomes in patients with brain metastases, particularly those with lung cancer.
Read More
